upadacitinib
AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa
July 25, 2023Research and Development AbbVie, Dermatology, HS, Rinvoq, clinical trial, upadacitinib
AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up trial assessing Rinvoq (upadacitinib) for …
AbbVie unveils new Phase 3 upadacitinib data in moderate to severe ulcerative colitis
December 10, 2020Research and Development AbbVie, upadacitinib
AbbVie has announced data from the first of two Phase 3 studies investigating the efficacy of upadacitinib in treating moderate …
AbbVie’s Rinvoq smashes Phase 3 efficacy targets in atopic dermatits
July 22, 2020Research and Development AbbVie, atopic dermatits, pharma, upadacitinib
AbbVie has lifted the curtain on data from the second Phase 3 trial investigating the efficacy of Rinvoq (upadacitinib) monotherapy …
AbbVie’s rheumatoid arthritis drug bests even its own blockbuster Humira at Phase 3
April 11, 2018Research and Development AbbVie, Humira, pharma, rheumatoid arthritis, upadacitinib
AbbVie posted a strong showing this week from its JAK1 inhibitor upadacitinib, indicating that the drug outperformed even its own …
Latest content
Five Facts about NHS and primary care
September 5, 2026
AI in pharma: From lab development to patient impact
September 5, 2026
